Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Oculis S.A.
Private Company Edition: Dyno’s first VC round will enable more deals for its novel AAV platform; Eikon pioneers new drug discovery technology. Also, Treeline’s early funding revealed at $211.7m; Capsida raised $140m from a VC round, AbbVie deal; and Affinia closed a $110m series B round.
The CEO of Oculis tells Scrip the Swiss biotech can become a major ophthalmic player and that its lead asset could become the first topical drug treatment for retinal edema.
Oculis’s eyedrop OCS-01 showed high efficacy treating post-cataract inflammation in front of the eye, adding to its effective use in back-of-the-eye conditions.
The Swiss biotech believes the clinical success of OCS-01, a novel eye drop formulation of dexamethasone for diabetic macular edema, validates not only the drug but also Oculis's proprietary technology, allowing it to build up a pipeline of products for both retinal and front of the eye diseases.
- Drug Delivery
- Controlled Release
Drug Discovery Tools
- Drug Discovery Tools